Helix BioMedix, Inc.
Helix BioMedix, Inc.
Your view on HXBM
Overview
What the company does, where it operates, and who runs it.
About Helix BioMedix, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Robin L. Carmichael
- Headquarters
- 22121-17th Avenue SE, Bothell, WA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Robin L. Carmichael
- Headquarters
- 22121-17th Avenue SE, Bothell, WA, US
Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States.
It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections.
The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Helix BioMedix, Inc., and the rating behind it. HXBM last traded at $2.70; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Helix BioMedix, Inc.. Starting points for Helix BioMedix, Inc.: EPS -$2.45, beta 0.63 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Helix BioMedix, Inc.. Helix BioMedix, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Helix BioMedix, Inc.. Trailing twelve-month EPS for Helix BioMedix, Inc. stands at -$2.45. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Helix BioMedix, Inc.. Helix BioMedix, Inc. has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Helix BioMedix, Inc. valued side by side against its closest peers. Helix BioMedix, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Helix BioMedix, Inc., and how their positions are changing. At a $606,712 market value, institutional positions materially move Helix BioMedix, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Helix BioMedix, Inc. executives and directors. Shares of Helix BioMedix, Inc. have traded between $1.75 and $7.19 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Helix BioMedix, Inc.. Helix BioMedix, Inc. is a $606,712 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Helix BioMedix, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Helix BioMedix, Inc.. Coverage tracks Helix BioMedix, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.